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BACKGROUND: Acute myocardial infarction is associated with tissue inflammation. Early coronary reperfusion clearly improves 
the outcome but may help propagate the inflammatory response and enhance tissue damage. Cyclooxygenase-2 is an enzyme that 
catalyzes the initial step in the formation of inflammatory prostaglandins from arachidonic acid. Cyclooxygenase-2 levels are in-
creased when ischemic cardiac events occur. The overall function of COX-2 in the inflammatory process generated by myocardial 
ischemic damage has not yet been elucidated.
GOAL: The objective of this study was to determine whether a selective cyclooxygenase-2 inhibitor (rofecoxib) could alter the 
evolution of acute myocardial infarction after reperfusion.
METHODS AND RESULTS: This study was performed with 48 mongrel dogs divided into two groups: controls and those treated 
with the drug. All animals were prepared for left anterior descending coronary artery occlusion. The dogs then underwent 180 
minutes of coronary occlusion, followed by 30 minutes of reperfusion. Blood samples were collected from the venous sinus im-
mediately before coronary occlusion and after 30 minutes of reperfusion for measurements of CPK-MB, CPK-MBm and troponin 
I. During the experiment we observed the mean blood pressure, heart rate and coronary flow.
The coronary flow and heart rate did not change, but in the control group, there was blood pressure instability, in addition to maximal 
levels of CPK-MB post-infarction. The same results were observed for CPK-MBm and troponin I.
CONCLUSION: In a canine model of myocardial ischemia-reperfusion, selective inhibition of Cyclooxygenase-2 with rofecoxib 
was not associated with early detrimental effects on the hemodynamic profile or the gross extent of infarction; in fact, it may be 
beneficial by limiting cell necrosis.
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INTRODUCTION
Acute myocardial ischemic injury is associated 
with various pathophysiological responses, including 
inflammatory activity with migration of neutrophils to 
the ischemic site. Although early blood reperfusion to the 
ischemic myocardium is undoubtedly beneficial in the setting 
of acute myocardial infarction, there is much evidence that 
re-establishment of coronary blood flow helps propagate 
inflammatory processes, enhancing tissue destruction and 
contributing to myocardial dysfunction.1,2 
Attempts to limit myocardial necrosis and improve 
outcomes in acute myocardial infarction by modulating the 
inflammatory process have long been proposed. Around 
thirty years ago, investigators demonstrated that some, but 
not all, anti-inflammatory agents could reduce the size of 
myocardial infarction in laboratory animals.3 On the other 
hand, no clear benefits and even evidence of deleterious 
effects were seen in human studies of anti-inflammatory 
drugs in acute coronary syndromes,4-7 although meloxicam 
was associated with a better outcome in a small trial.8
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More recently, with the advent of selective cyclooxygenase 
(COX)-2 inhibitors, the issue of anti-inflammatory drugs in 
acute myocardial infarction has again been brought to the 
forefront. COX is an enzyme that converts free arachidonic 
acid into prostaglandins, which mediate inflammation. 
Differing from the COX-1 isoform, which is constitutively 
expressed and has a housekeeping role, COX-2 is usually 
absent or minimally present in most tissues but is induced 
under certain conditions such as inflammation. Indeed, COX-
2 is typically considered a pro-inflammatory enzyme, and 
selective COX-2 inhibitors have been widely prescribed for 
acute and chronic inflammatory disorders. Importantly, this 
class of drugs has been associated with adverse cardiac events 
in humans, raising serious concerns about their safety.9-13 The 
mechanisms by which COX-2 inhibitors may harm the heart 
have not been fully elucidated. It has been shown that under 
certain circumstances, COX-2 possesses other properties, 
including inhibition of fibrosis, thrombosis and even 
inflammation14-16 which may play a cardioprotective role.
Investigations focusing on COX-2 and COX-2 inhibitors 
in different models of myocardial ischemia/infarction in 
diverse animals have elicited contradictory findings, bringing 
more controversy to this issue. While several studies have 
shown that COX-2 inhibition protects the heart and preserves 
cardiac function in murine models of myocardial ischemia/
infarction,17-21 celecoxib was shown to deteriorate myocardial 
function and increase mortality after myocardial infarction 
in pigs.22
Importantly, these studies evaluated the consequences of 
complete ligation of a coronary artery, without reperfusion, 
on cardiac function over several days or weeks. In a clinical 
setting, early coronary reperfusion is not only desirable but 
also increasingly frequent, now that fibrinolytic therapy and 
percutaneous intervention have become more accessible. 
Moreover, it is known that it is during the first moments after 
an acute myocardial infarction that the subjects are the most 
susceptible to complications. The effects of COX-2 inhibition 
in the very early phase after an acute myocardial infarction 
with coronary reperfusion have not been well addressed. 
In rabbits, it appears that COX-2 has an essential role in 
cardioprotection conferred by ischemic preconditioning23; 
accordingly, COX-2 inhibition was shown to exacerbate 
ischemia-induced acute myocardial dysfunction in an in vitro 
perfused rabbit heart model.24
This study was designed to help elucidate the role 
of COX-2 and the mechanisms involved in the effect of 
selective COX-2 inhibitors in the very early phase of acute 
myocardial infarction followed by coronary reperfusion. 
Specifically, this study aimed to evaluate the effect of pre-
treatment with rofecoxib, a selective COX-2 inhibitor, on 
the extent of infarction, biomarkers of cardiac necrosis and 
hemodynamic behavior in a well-established canine model 
of myocardial ischemia-reperfusion.
MATERIAL AND METHODS
This study was approved by the Ethics in Research 
Committee of our institution (Protocol 2165/02/172), 
according to the American Heart Association regulations 
for Research Involving Animals, based on the “Guide for 
the Care and Use of Laboratory Animals” (National Health 
Council publication, National Academy Press, Washington, 
D.C 1996.)63 63A
The dogs used in this experiment were obtained from the 
Public Health System, Urban Zoonosis Department. After 
being properly cleaned, the animals were housed in the biotery 
in isolated cages with veterinary care for several days before 
the surgery was carried out. They were fed commercial dog 
feed and water ad libitum, and they were vaccinated against 
rabies (hydrophobia) and given a dose of vermicide. Forty-
eight adult male dogs (Canis familiaris) were studied: 28 
dogs were part of the study group treated with commercial 
rofecoxib (Vioxx®, MK-966) at a single 50-mg/day dose per 
os with their chow during the 48 hours preceding the surgical 
procedure, while 20 dogs were part of the control group. The 
weight of the animals ranged from 15 to 30 kg. Rofecoxib 
is rapidly absorbed after oral administration. In dogs, a peak 
concentration of 207 ng/ml (0.6585 µM) was achieved 2 to 3 
hours after oral administration of a single 25-mg dose.61-63
In both groups, the animals were anesthetized, intubated 
and artificially ventilated. They underwent thoracotomy 
and dissection of the anterior descending coronary artery. 
The following hemodynamic parameters were evaluated: 
coronary blood flow, average blood pressure and heart rate. 
Immediately before the occlusion, blood was collected from 
the venous sinus to evaluate creatine phosphokinase-MB 
(CPK-MB), CPK-MB mass and troponin-I levels. This 
procedure was followed by a 180-minute occlusion and 
a 30-minute reperfusion. After completing the 30-minute 
reperfusion, a new blood sample from the venous sinus was 
collected to evaluate the same biochemical markers.
At the end of each experiment, all dogs received a dose 
of 30 mg/kg of sodium pentobarbital before euthanasia 
with potassium chloride. Following this procedure, their 
hearts were excised and submitted to Evans blue and 
triphenyltetrazolium chloride staining to define the risk areas 
and areas of infarction. 
MONITORING AVERAGE BLOOD PRESSURE, 
HEART RATE AND CORONARY FLOW
A 7F polyethylene catheter was positioned in the left 
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carotid artery for continuous monitoring of the average 
blood pressure (ABP) and heart rate (HR). The catheter was 
connected to a Biopac Systems transducer, TSD-104 Model 
(Biopac Systems, Santa Barbara, CA, USA), linked to a 
computer with specific software (Acknowledge) to read the 
hemodynamic values. Central venous access was obtained 
through cannulation of the left internal jugular vein by 
means of another 7F polyethylene catheter to infuse liquids 
and anesthetic.
Coronary flow was measured with placement of an 
electromagnetic flow-transducer (Transonic Systems Inc., 
Probe 2S) in the ADA in its proximal third, immediately 
after the emergence of the first diagonal branch.
DETERMINING THE LEVELS OF CPK-MB, CPK-
MB MASS AND TROPONIN I
Quantitative determination of the MB isoform of creatine 
kinase was performed by means of in vitro immune assays, 
using an automatic analyzer Roche/Hitachi model 912 
(Roche Diagnostics, Indianapolis, IN, USA)
This method presupposes that CK-MB is made up of two 
subunits: CK-M and CK-B, both with an active site. The test 
consists of adding a polyclonal antibody directed against the 
CK-M site to the serum, which almost completely (99.6%) 
inhibits the catalytic ability of the CK-M subunit without 
affecting the CK-B subunit. The remaining activity of the 
CK-B subunit is equal to half of the activity of CK-MB. 
The catalytic activity of CK-MB can be calculated as the 
measured CK-B activity multiplied by 2, since the CK-BB 
isoform rarely appears in the serum.53,54
For the measurement of creatine kinase-MB mass, 
immunochemiluminescence with laboratory automation was 
used by means of “Immulite” DPC equipment (Diagnostic 
Products Corporation – Los Angeles, CA, USA). In this 
method, the serum is put into contact with small spheres 
covered by anti-CK-MB murine monoclonal antibody (Turbo 
CK-MB test unit - SCP1). A second test unit is then added 
(Turbo CK-MB – SCP2), containing alkaline phosphatase 
conjugated to an anti-CK-MB murine polyclonal antibody. 
Upon reacting, both units cause the release of luminescence, 
quantified by the Immulite equipment.55,56
Fo r  m e a s u r e m e n t  o f  t r o p o n i n  I ,  i m m u n o -
chemiluminescence with laboratory automation was used 
by means of Immulite DPC equipment (Diagnostic Products 
Corporation – Los Angeles, CA, USA). In this method, the 
serum is put into contact with small spheres covered by anti-
troponin I rat monoclonal antibody (Turbo Troponin I – STI1 
test unit). Thereafter, a second test unit (Turbo Troponin I – 
STI2) is added, containing alkaline phosphatase conjugated 
with anti-troponin I goat polyclonal antibody. Upon reacting, 
both units cause the release of luminescence quantified by 
the Immulite equipment. 55,56
ANATOMIC DEFINITION OF THE NORMOPER-
FUSED, ISCHEMIC AND INFARCTION AREAS
The regions of the left ventricular myocardium with 
normoperfusion, ischemia and infarction were evaluated at 
the end of each experiment by the techniques described by 
Jolly et al57 and Chagas.58
At the end of the protocol, the hearts were excised. 
The ADA was then occluded at the same place in which 
the occlusor was positioned and cannulated distal to the 
occlusion. Evans blue stain (1 mg/kg) was infused through 
a catheter positioned in the right coronary artery and in the 
left coronary artery trunk, and simultaneously, a solution 
at 2% CTT was injected into the ADA. Thus, the areas that 
were not perfused by the ADA were stained by Evans blue, 
delimiting the region at risk supplied by the ADA. The heart 
was then sectioned longitudinally and incubated in a CTT 
solution at 37oC for 30 minutes. This technique stains the 
viable myocardium in bright red and the necrotic tissue in 
a pale yellow shade. The regions that did not show a bright 
red color and remained a pale yellow shade were defined as 
necrotic myocardium.59,60
STATISTICAL ANALYSIS
Initially, all variables were analyzed descriptively. With 
regard to the quantitative variables, analysis was carried out 
by observation of the minimum and maximum values and 
the calculation of averages and standard deviations. For the 
qualitative variables, absolute and relative frequencies were 
calculated.
To analyze the hypothesis of average equality between 
the two groups, a Student’s t-test25 was used, which allows 
the evaluation of variables at a single period between the 
control and treated groups. This method was used to analyze 
the weight of the fragments of the left ventricle.
In the hemodynamic analysis of the groups, the 
Analysis of Variance (ANOVA) technique with repeated53 
measurements was used, which consists of the adjustment 
of a multivariate linear model.
RESULTS
Initially, the study included 61 dogs, but 13 dogs were 
excluded because they exhibited ventricular fibrillation 
during the coronary artery occlusion. Electric cardioversion 
could not be used because it can alter serum levels of 
necrosis markers.
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Figure 1 - Graph showing values of CPK-MB during the pre and post-
infarction periods in the control dogs and in the dogs treated with icox-2
Figure 2 - Graph of the values of CPK-MB mass during the pre and post 
infarction periods in the control dogs and in the dogs treated with icox-2
Figure 3 - Graph showing values of Troponin I during the pre and post-
infarction periods in the control dogs and in the dogs treated with icox-2
The arterial blood pressure drop in the basal period as 
compared to the arterial blood pressure in the 1st minute of 
occlusion showed a sharp drop (p<0.001) in both groups. 
There was a significant arterial blood pressure increase 
(p<0.001) between the 1st and 30th minute in the control 
group; however, this was not observed in the treated group 
(p=0.2257). It was also observed that the arterial blood 
pressure at the 30th minute did not significantly differ 
from that at the 180th minute, in either the control group 
(p=0.2576) or the treated group (p=0.0546). It was observed, 
however, that the arterial pressure at the 180th minute differed 
from that at the 1st minute of reperfusion in the control 
group (p=0.0056), while the same drop in pressure was not 
observed in the treated group (p=0.3973). 
Using ANOVA with repeated measurements, we observed 
that both groups showed the same heart rate throughout the 
study period (p=0.1015). The groups did not show significant 
differences between their averages (p=0.2013) and showed 
the same significant changes throughout the study (p< 
0.001), indicating that there was homogeneity in heart rate 
among the groups.
The two groups also showed the same cardiac flow 
behavior throughout the experiment (p=0.5315). They did 
not show significant differences between their averages 
(p=0.4118) and showed the same significant changes 
throughout the experiment (p< 0.001). The basal period 
differed from the 1st minute of reperfusion (p< 0.001), and 
this differed from the 30th minute of reperfusion (p< 0.001) 
in both groups, showing that both groups had reactive 
hyperemia, characteristic of reperfusion.
No significant changes were observed in the 
normoperfused areas between the studied groups (p=0.1648). 
The same results were obtained for the ischemic areas 
(p=0.3651) and the infarction area (p=0.2793). 
Using ANOVA with repeated measurements, we observed 
that the two groups showed a significant increase in CPK-
MB between pre- and post-infarction (p<0.001), indicating 
that both groups suffered acute myocardial infarction. The 
control group showed significantly higher averages of CPK-
MB than the treated group during the post-infarction period 
(p=0.0445) (Figure 1). 
The control and treated groups showed a significant 
increase in the level of the CPK-MB mass between the pre- 
and post-infarction periods (p<0.001), with no difference 
between their averages during pre-infarction (p=0.2408). 
During the post-infarction period, however, we observed 
a significant CPK-MB mass increase in the control group 
(p=0.007), as compared to the treated group (Figure 2).
The two groups showed a significant difference in 
troponin I levels during the pre- and post-infarction periods 
(p<0.001). The groups showed no difference between 
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levels during pre-infarction (p=0.6275), but troponin I was 
increased in the control group (p<0.001) during the post-
infarction period, as compared to the group treated with 
icox-2 (Figure 3).
DISCUSSION
The current study shows that the use of a specific 
cyclooxygenase-2 inhibitor in experimental acute myocardial 
ischemia models results in a protective effect on cardiac 
muscle.
In the analysis of blood pressure, two periods of pressure 
instability were observed: one occurred during the period in 
which the coronary occlusion was performed (detected at 
1 min), and the other occurred during the period in which 
the coronary was reperfused (detected in the 1st minute of 
reperfusion). This statistically significant pressure drop was 
only observed in the control group, as the treated group did not 
show arterial pressure instability during these two periods.
This effect of a selective cyclooxygenase-2 inhibitor on 
the systolic, diastolic and average blood pressure has also 
been observed in other studies.26-28 The most commonly 
accepted hypothesis is related to the effect of sodium 
reabsorption by the kidneys when the cyclooxygenase-2 
inhibitor is administered, without affecting glomerular 
filtration.
In a recent study by Höcherl et al.,29 cardiac dysfunction 
and blood pressure were evaluated in rats undergoing 
intravenous infusion of lipopolysaccharides. These animals 
were divided into two groups: the treated group received 
a specific cyclooxygenase-2 inhibitor (rofecoxib), and the 
control group was untreated. A significant decrease in blood 
pressure and myocardial dysfunction was observed in the 
control group. These pathological changes were not observed 
in the group treated with the COX-2 inhibitor. The blood 
pressure observations of Höcherl et al.29 were similar to those 
obtained in our experiment, in which the group treated with 
iCOX-2 did not show a sharp drop in blood pressure during 
the periods when the coronary occlusion and reperfusion 
were performed. Despite these results, the exact mechanism 
by which selective cyclooxygenase-2 inhibitors interfere 
with blood pressure remains to be explained.
No changes in coronary flow were observed between the 
groups in our study. Our results were similar to those of a 
study by Verma et al.,30 who used plethysmography in the 
forearm of volunteers and healthy patients to evaluate the use 
of rofecoxib, as compared to infusion of acetylcholine and 
sodium nitroprussiate. It was observed that the patients did 
not show blood flow changes, suggesting that the selective 
COX-2 inhibitor did not stop the vasodilatation mechanisms 
mediated by the endothelium.
In our biochemical analysis, we used the same 
methods used in clinical analysis laboratories for human 
measurements. Such methods are also valid for laboratory 
animals.31,32 Each animal served as its own control between 
the pre-infarction and the post-infarction period, and the 
obtained values were in accordance with those found in 
other studies.31,32
Considering the kinetics of the analyzed biochemical 
markers in the circulation (e.g., cell compartmentalization, 
linkage to plasma molecules, distribution, degradation 
and elimination), the subjects only have detectable plasma 
levels in the peripheral circulation from four to five hours 
after the coronary ischemic event.31 Due to the metabolic 
and distributive kinetics of CPK-MB, CPK-MB mass and 
troponin I, we collected blood samples by central venous 
access (from the coronary sinus) after 30 minutes of 
coronary reperfusion, i.e., three and a half hours after the 
start of the ischemic event. This allowed sufficient time33-
35
 to obtain detectable plasma levels by the biochemical 
methods used.
Previous studies36,37 making use of non-steroid anti-
inflammatories showed that these medications did not have 
a cardioprotective effect during ischemic injury, but there is 
still no exact definition of their role in cardiomyocytes.38,39
Ischemic inflammatory myocardial injury began during 
the period in which the blood supply was interrupted and 
increased during the period of coronary reperfusion40,41, 
along with a greater expression of COX-234 mRNA.
A study by Metais et al35 showed that increased COX-
2 levels in the microvasculature of pig ventricles were 
related to an increase in local vasoconstriction. This 
vasoconstriction, however, was inhibited by the use of a 
selective cyclooxygenase-2 inhibitor. These results could 
explain, in part, the results of our current study, in which we 
observed biochemical signs of myocardial cytoprotection in 
acute myocardial infarction with treatment with a selective 
cyclooxygenase-2 inhibitor.
We found significantly lower values for the biochemical 
markers in the treated group, as compared to the control 
group, due to the use of rofecoxib. The values of CPK MB 
were obtained through the least sensitive detection method 
(p=0.0445). Immunochemiluminescence with electronic 
reading, however, which was used to detect CPK MB mass 
(p=0.007) and troponin I (p<0.001), is a more sensitive 
assay.
Although significant differences were observed between 
the groups for the biochemical markers, indicating possible 
myocardial cytoprotection in the setting of an acute ischemic 
stimulus, these differences were not observed in the 
quantification of the normoperfused, ischemic or infarcted 
tissue.21-23,42 
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Clinical implications for the use of selective cyclooxyge-
nase-2 inhibition and cardiovascular events
Some questions are still open. Is there really a 
relationship between coxibs and the increase in the number 
of ischemic cardiac events? If so, how can we explain this 
pathophysiology? Are these pathophysiological mechanisms 
dependent on a coxib class effect, or are they only caused by 
a specific kind of selective cyclooygenase-2 inhibitor?
The VIGOR study (Vioxx Gastrointestinal Outcomes 
Research trial) was the first great study to discuss the 
presence of cardiovascular events with the use of icox-2. 
Meanwhile, results from a metanalysis43 involving rofecoxib 
showed that naproxen, used in the VIGOR study, has a 
protective effect, whereas the rofecoxib group went without 
this protection. Another important piece of information 
pertaining to this study was that the analyzed population 
consisted of patients with rheumatoid arthritis. These 
patients have a higher risk of cardiovascular events, and 
this compromises the results of the VIGOR study. On the 
other hand, a study44 of 150 patients using rofecoxib, who 
underwent isolated coronary artery bypass graft surgery, 
showed that there was no clinical evidence for a deleterious 
effect of rofecoxib on myocardium in these patients.
Differences in the chemical structures of the 
various coxibs result in different pharmacological and 
pharmacokinetic proprieties that could theoretically explain 
why one coxib is more toxic than another of the same class. 
There are no studies, however, that evaluate cardiovascular 
events and compare one coxib with another of the same 
class, which might support this theory.45 On the other hand, 
a study developed by Andersohn et al.46 in which patients 
with acute myocardial infarction were evaluated, suggested 
that the toxicity could be related to the entire coxib class. 
However, these authors compared icox-2 drugs to a non-
selective COX inhibitor (diclofenac), similar to the VIGOR 
study.
Meanwhile, an experimental study conducted by Delgado 
et al. demonstrated that cyclooxygenase-2 inhibition could 
attenuate the development of cardiac heart failure after 
myocardial lesions, as evidenced by improved left ventricular 
ejection fraction and a reduction in animal mortality.47 
Further ongoing trials are investigating the newer coxibs 
as well as the older drugs, but unfortunately, they are mostly 
being performed in patients with rheumatoid arthritis, as in 
the CLASS and the TARGET studies. It is already known 
that rheumatoid arthritis itself is a risk factor for cardiac 
disease, most likely due to a chronic increase in circulating 
cytokine concentrations as well as in C reactive protein and 
other proatherogenic inflammatory markers, with activation 
of leucocytes in both processes.48
Another study showed that the use of icox-2 was able 
to reduce endothelial oxidative stress and the generation of 
ionic forms (nitric oxide induced synthase), peroxynitrite 
and superoxide and the formation of interleukins 6 and 8. 
These reductions in endothelial oxidative stress provoked 
improvement in endothelium-dependent vasodilatation, 
resulting in the improvement of heart failure disease.49 
Moreover, an increase in serum VEGF (Vascular Endothelial 
Growth Factor) was not suppressed by treatment with icox-2 
, indicating that VEGF was induced in a COX-2-independent 
manner.50, 51
Recently, another experimental study52 showed, for the 
first time, a functional improvement with the administration 
of parecoxib, a selective COX-2 inhibitor, in an animal 
model of ischemic congestive heart failure. Confirming these 
findings, a functional improvement with COX-2 inhibitors in 
a model of non-ischemic heart failure was already shown and 
was paired with a significant reduction in mortality.46
Cumulative data currently suggest that the mechanisms 
of acute myocardial infarction and inflammation have 
different phases in which the same component (e.g., 
cyclooxygenase-2) can be beneficial in a given moment 
but have a different effect at another moment. Thus, 
further studies are needed to clarify the pathophysiological 
mechanisms linking inflammatory activity to acute 
myocardial infarction.
CONCLUSION 
The results of this study have shown that the use of a 
specific cyclooxygenase-2 inhibitor, rofecoxib, might be 
beneficial in reducing the intensity of myocardial injury 
induced by acute coronary occlusion in dogs. New clinical 
studies related to endothelial dysfunction and inflammation 
are necessary, however, in order to elucidate the complete 
role of inflammatory mechanisms in acute myocardial 
infarction.
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